Regen BioPharma, Inc. (OTCQB: RGBP) is engaged in the development, research, and commercialization of regenerative medical treatments across the United States. Shares of the specialty pharmaceutical company are soaring 68.52%, through early trading on Thursday, March 2, 2017. Over the past three months, Regen BioPharma, Inc. has seen average daily volume of 111,146 shares. However, volume of 1.83 million shares or dollar volume of $164,700, has already exchanged hands Thursday.
Shares of Regen BioPharma, Inc. are climbing Thursday, after the company announced that it has signed a licensing agreement with CheckPoint Immunology, Inc. Under the agreement, CheckPoint Immunology, Inc. gains an exclusive global license to develop and market Regen’s NR2F6 technology, which is used for human therapeutic use. Here is the full press release detailing of the licensing agreement:
Regen BioPharma, Inc. Press Release:
SAN DIEGO, March 2, 2017 /PRNewswire/ –CheckPoint Formed as a Subsidiary of the Company to Simplify any Potential Future Transactions Involving the Company’s NR2F6 Technology
Regen BioPharma, Inc. (RGBP), (RGBPP) has granted CheckPoint Immunology Inc. (a wholly-owned subsidiary of the Company) an exclusive worldwide license to develop and commercialize Regen’s NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen’s small molecule technology from its other intellectual property in order to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.
The Company’s focus on NR2F6 has two developmental streams. The first area of development involves the inhibition of the checkpoint, NR2F6, in order to cause the body’s immune system to destroy cancer cells. The second area of development involves the activation of NR2F6 which is believed to be a fulcrum for curing such autoimmune diseases as rheumatoid arthritis.
Regen BioPharma’s Chairman and CEO, David Koos, stated, “In the beginning, Regen’s business model was created with the goal of developing intellectual property to a point of attracting large pharmaceutical companies, to participate in maturing Company assets, either by sale, license or co-development. By forming CheckPoint Immunology, we are setting our game plan in place so that as we get further along in our development of small molecule therapies for treating cancer and autoimmune diseases, we can structure a transaction specific to NR2F6-related therapies. The Company has been approached by numerous parties interested in our NR2F6 based therapies. We expect, as we further optimize our small molecule compounds, there should be even greater interest. Hence the reason for creating CheckPoint Immunology is as a pure vehicle for any future NR2F6 transaction.”
Dr. Harry Lander, Regen’s president and CSO, noted, “Biotechnology companies focused on successful immune-oncology therapies are generally granted trophy value transactions (e.g., deals that have a value in excess of $1 billion). In addition to our intent to create a first-in-class immune checkpoint inhibitor for treating cancers, we also plan to exploit the anti-autoimmune aspects of our small molecules as well. Thus, while we can’t anticipate what our valuation will be if our programs pan out, it’s good to know we’re swimming in the right pool.”
Currently CheckPoint Immunology is at the lead optimization phase of its medicinal chemistry program. The Company anticipates that once results of the medicinal chemistry program being conducted by ChemDiv, Inc. are available, we should be in a position to form alliances with large companies interested in NR2F6 inhibition for cancer therapy or NR2F6 activation for treating autoimmune disorders.
Regen is also party to an agreement whereby Zander Therapeutics, Inc. has been granted by Regen, an exclusive worldwide right and license for the development and commercialization of NR2F6 intellectual property controlled by Regen for non-human veterinary therapeutic use. Zander Therapeutics Inc. is a wholly-owned subsidiary of Entest BioMedical Inc. (ENTB). David R. Koos serves as Chairman and Chief Executive Officer of Regen, Entest Biomedical, Inc. and Zander Therapeutics.
About Regen BioPharma, Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
About Zander Therapeutics, Inc.:
Zander Therapeutics is a wholly-owned subsidiary of Entest BioMedical Inc. (ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary application. Currently, the Company’s major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc. (RGBP) (RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as an ‘orphan nuclear receptor’, which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (RGBP), Entest BioMedical Inc. (ENTB) and Zander Therapeutics Inc. (wholly-owned by Entest BioMedical Inc.).
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.